Hydration Intervention to Decrease Side Effects Associated With GLP - 1 RA Therapy

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorState University of New York at Buffalo

About this trial

This is a 17 - week study consisting of a one - week run - in period and a 16 - week intervention. The 16 - week pilot interventions aims to increase hydration in those beginning GLP - 1 RA therapy. Investigators aim to increase hydration to potentially decrease side effect severity, amount of side effects, and drug discontinuation associated with GLP - 1 RA therapy. The investigators are piloting to assess feasibility and preliminary efficacy of the intervention through examining participant retention, participant feedback, researcher and participant adherence to protocols, impact on hydration biomarkers, and participant reported GLP - 1 RA side effects.

Eligibility criteria

Qualifiers

Adults aged 18-60

Recently prescribed a GLP-1RA (within one week of prescription)

Fluent in English

Willing to complete the study protocol

Disqualifiers

Children and adults > 60 years of age

Those not taking a GLP-1RA

Those who have been on a GLP-1RA longer than one week

Not fluent in English

Trial design

Treatments tested in this trial

  • Hydration Plus
  • Control

Treatment groups

30 Participants
are divided into 2 treatment groups

Sponsors and collaborators

State University of New York at Buffalo

Lead sponsor

National Institutes of Health (NIH)

Collaborator